Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2010

01-06-2010 | Original Article

Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US

Authors: Ramsey Cheung, Ajitha Mannalithara, Gurkirpal Singh

Published in: Digestive Diseases and Sciences | Issue 6/2010

Login to get access

Abstract

Background

Studies on mostly veterans found the majority of chronic hepatitis C (CHC) patients were not treated. Little information exists on a broad-based population.

Aims

To determine the national trend of ambulatory visits with a diagnosis of hepatitis C and the prescription of antiviral therapy associated with such visits.

Methods

Retrospective analysis of national cross-sectional databases, the National Ambulatory Medical Care Survey (NAMCS), and the National Hospital Ambulatory Medical Care Survey (NHAMCS) encompassing all ambulatory visits from 2000 to 2006.

Results

During the study period, 16.5 million visits (0.21% of all visits) carried a diagnosis of hepatitis C and the number initially increased. Characteristics of the hepatitis C patients were: 65% male; 71% white, 22% black; 69% ≥45 years old. Overall, 47% had private insurance, 24% had Medicaid, and 12% had Medicare. Only 9.1% of these patients were prescribed antiviral treatment for CHC. There was no significant difference between those who received treatment and those who did not in terms of age, gender, race, and insurance status. HIV infection, mood, substance-use disorders, and anemia were more common in the CHC group.

Conclusions

Less than 10% of the ambulatory visits for hepatitis C were associated with a prescription for antiviral therapy, independent of demographic and insurance status. Purposes of the clinic visits were different in the CHC group compared to the general population. The reason for the low treatment rate is not clear but deserves further investigation.
Literature
1.
go back to reference Armstrong GL, Wasley A, Simard EP, McQuillan GM, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.PubMed
2.
go back to reference Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389.CrossRefPubMed Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385–389.CrossRefPubMed
3.
go back to reference Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004;10:250–256.PubMed Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004;10:250–256.PubMed
4.
go back to reference Bobbola M, Momi J, Lim JK, Ready J, Cheung RC. Practice patterns and treatment outcomes in the management of chronic hepatitis C (CHC) in a large management care cohort. Abstract presented at the annual meeting of the American College of Gastroenterology; 2005. Bobbola M, Momi J, Lim JK, Ready J, Cheung RC. Practice patterns and treatment outcomes in the management of chronic hepatitis C (CHC) in a large management care cohort. Abstract presented at the annual meeting of the American College of Gastroenterology; 2005.
5.
go back to reference Manos M, Shvachko V, Zhao W, Murphy RC. Determinants of HCV antiviral treatment in a managed care setting. Hepatology. 2008;48:866A. Manos M, Shvachko V, Zhao W, Murphy RC. Determinants of HCV antiviral treatment in a managed care setting. Hepatology. 2008;48:866A.
6.
go back to reference Cherry DK, Hing E, Woodwell DA, Recher EA. National ambulatory medical care survey: 2006 Summary. National Health Statistics Reports, Number 3, August 6; 2008. Cherry DK, Hing E, Woodwell DA, Recher EA. National ambulatory medical care survey: 2006 Summary. National Health Statistics Reports, Number 3, August 6; 2008.
9.
go back to reference Cheung RC, Cunningham BA, Cooper AD. Effectiveness of a screening program for hepatitis C. Dig Dis Sci. 2006;51:976–981.CrossRefPubMed Cheung RC, Cunningham BA, Cooper AD. Effectiveness of a screening program for hepatitis C. Dig Dis Sci. 2006;51:976–981.CrossRefPubMed
10.
go back to reference Falck-Ytter Y, Kate H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.PubMed Falck-Ytter Y, Kate H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.PubMed
11.
go back to reference Araya V, Basi PS, Feyssa E, Malek A, et al. The majority of HCV-infected patients presenting to a large hepatology practice in an urban setting cannot be treated with pegylated interferon and ribavirin due to psychosocial factors in spite of universal health insurance access. Gastroenterology. 2009;136(Suppl 1):S2079. Araya V, Basi PS, Feyssa E, Malek A, et al. The majority of HCV-infected patients presenting to a large hepatology practice in an urban setting cannot be treated with pegylated interferon and ribavirin due to psychosocial factors in spite of universal health insurance access. Gastroenterology. 2009;136(Suppl 1):S2079.
12.
go back to reference Muir AJ, Provenzale D. A descriptive evaluation of eligibility for treatment among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268–271.CrossRefPubMed Muir AJ, Provenzale D. A descriptive evaluation of eligibility for treatment among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268–271.CrossRefPubMed
13.
go back to reference Bini EJ, Brau N, Currie S, Shen H, et al. Prospective multicenter study of eligibility for anti-viral therapy among 4,084 U.S. veterans with chronic hepatitis C infection. Am J Gastroeneterol. 2005;100:1772–1779.CrossRef Bini EJ, Brau N, Currie S, Shen H, et al. Prospective multicenter study of eligibility for anti-viral therapy among 4,084 U.S. veterans with chronic hepatitis C infection. Am J Gastroeneterol. 2005;100:1772–1779.CrossRef
14.
go back to reference Groom H, Dieperink E, Nelson DB, Garrard J, et al. Outcomes of a hepatitis C screening program in a large urban VA medical center. J Clin Gastroenterol. 2008;42:97–106.CrossRefPubMed Groom H, Dieperink E, Nelson DB, Garrard J, et al. Outcomes of a hepatitis C screening program in a large urban VA medical center. J Clin Gastroenterol. 2008;42:97–106.CrossRefPubMed
15.
17.
go back to reference El-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476–482.CrossRefPubMed El-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476–482.CrossRefPubMed
18.
go back to reference Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl. 2003;9:331–338.CrossRefPubMed Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl. 2003;9:331–338.CrossRefPubMed
19.
go back to reference Myers RP, Liu M, Shaheen AA. The burden of hepatitis C infection is growing: a Canadian population-based study of hospitalization from 1994 to 2004. Can J Gastroenterol. 2008;22:381–387.PubMed Myers RP, Liu M, Shaheen AA. The burden of hepatitis C infection is growing: a Canadian population-based study of hospitalization from 1994 to 2004. Can J Gastroenterol. 2008;22:381–387.PubMed
20.
go back to reference Bruno S, Stroffolini T, Colombo M, Bollani S, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587.CrossRefPubMed Bruno S, Stroffolini T, Colombo M, Bollani S, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587.CrossRefPubMed
21.
go back to reference Veldt BJ, Heathcote JE, Wedemeyer H, Reichen J, et al. Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.PubMed Veldt BJ, Heathcote JE, Wedemeyer H, Reichen J, et al. Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.PubMed
22.
go back to reference John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M et al. Sustained responders have better quality of life and productivity compared with treatment failure long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009 (epub ahead of print). John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M et al. Sustained responders have better quality of life and productivity compared with treatment failure long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009 (epub ahead of print).
23.
go back to reference George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, et al. Clinical, virological, histological, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738.CrossRefPubMed George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, et al. Clinical, virological, histological, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738.CrossRefPubMed
24.
go back to reference Butt AA, Wang X, Moore CG. Effect of hepatitis C and its treatment on survival. Hepatology. 2009;50:387–392.CrossRefPubMed Butt AA, Wang X, Moore CG. Effect of hepatitis C and its treatment on survival. Hepatology. 2009;50:387–392.CrossRefPubMed
25.
go back to reference Berenguer J, Alverez-Pellicer J, Martin PM, Lopez-Aldeguer J, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complication and mortality in patients co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413.CrossRefPubMed Berenguer J, Alverez-Pellicer J, Martin PM, Lopez-Aldeguer J, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complication and mortality in patients co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413.CrossRefPubMed
26.
go back to reference Butt AA, Khan UA, Shaikh OS, McMahon D, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10:25–32.CrossRefPubMed Butt AA, Khan UA, Shaikh OS, McMahon D, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials. 2009;10:25–32.CrossRefPubMed
27.
go back to reference Butt AA, Tsevat J, Leonard AC, Shaikh OS, et al. Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis. 2009;13:449–455.CrossRefPubMed Butt AA, Tsevat J, Leonard AC, Shaikh OS, et al. Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis. 2009;13:449–455.CrossRefPubMed
28.
go back to reference Pyenson B, Fitch K, Iwasaki K. Consequences of Hepatitis C Virus (HCV): Cost of a Baby Boomer Epidemic of Liver Disease. Seattle: Milliman, 2009. Commissioned by the Vertex Pharmaceuticals Incorporated. Pyenson B, Fitch K, Iwasaki K. Consequences of Hepatitis C Virus (HCV): Cost of a Baby Boomer Epidemic of Liver Disease. Seattle: Milliman, 2009. Commissioned by the Vertex Pharmaceuticals Incorporated.
29.
go back to reference Zhang H, Mehra M, DiBello J. Increase in CHC Treatment Rate in the US is a Cost-saving Strategy. Presented at the 44th annual meeting of the European Association for the Study of the Liver. Copenhagen, Denmark, April 22–26, 2009. Zhang H, Mehra M, DiBello J. Increase in CHC Treatment Rate in the US is a Cost-saving Strategy. Presented at the 44th annual meeting of the European Association for the Study of the Liver. Copenhagen, Denmark, April 22–26, 2009.
30.
go back to reference Zhang H, Mehra M, DiBello J. US Hepatitis C Burden Assessment from a Transmission Model. Presented at the 44th annual meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, April 22–26 2009. Zhang H, Mehra M, DiBello J. US Hepatitis C Burden Assessment from a Transmission Model. Presented at the 44th annual meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, April 22–26 2009.
31.
go back to reference Ruhl CS, Sayer B. Summary of surveys used in the burden of digestive diseases in the United States. In: Everhart JE, ed. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 2008: NIH Publication No. 09-6443, pp. 153–155. Ruhl CS, Sayer B. Summary of surveys used in the burden of digestive diseases in the United States. In: Everhart JE, ed. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 2008: NIH Publication No. 09-6443, pp. 153–155.
Metadata
Title
Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US
Authors
Ramsey Cheung
Ajitha Mannalithara
Gurkirpal Singh
Publication date
01-06-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1147-z

Other articles of this Issue 6/2010

Digestive Diseases and Sciences 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine